HC Wainwright Trims Kura Oncology (NASDAQ:KURA) Target Price to $32.00

Kura Oncology (NASDAQ:KURA) had its price objective decreased by HC Wainwright from $43.00 to $32.00 in a research report released on Wednesday morning, Analyst Ratings Network reports. HC Wainwright currently has a buy rating on the stock.

KURA has been the topic of a number of other reports. SVB Leerink lifted their target price on Kura Oncology from $40.00 to $41.00 and gave the stock an outperform rating in a research report on Friday, August 6th. Credit Suisse Group decreased their target price on Kura Oncology from $42.00 to $40.00 and set an outperform rating for the company in a research note on Friday, August 6th. Wedbush reiterated an outperform rating on shares of Kura Oncology in a research report on Monday, November 8th. Finally, Zacks Investment Research upgraded Kura Oncology from a sell rating to a hold rating in a research report on Tuesday, October 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology currently has a consensus rating of Buy and an average price target of $42.71.

NASDAQ:KURA opened at $14.02 on Wednesday. The business’s 50-day moving average is $18.24 and its two-hundred day moving average is $19.58. Kura Oncology has a 12 month low of $12.32 and a 12 month high of $43.00. The firm has a market capitalization of $933.12 million, a PE ratio of -7.30 and a beta of 1.58.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, November 4th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.04. During the same period in the previous year, the business earned ($0.42) EPS. On average, research analysts predict that Kura Oncology will post -2.01 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. FORA Capital LLC bought a new stake in Kura Oncology during the second quarter worth approximately $27,000. Royal Bank of Canada raised its holdings in Kura Oncology by 56.4% during the third quarter. Royal Bank of Canada now owns 6,894 shares of the company’s stock worth $129,000 after purchasing an additional 2,487 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Kura Oncology by 31.7% in the second quarter. Virtus ETF Advisers LLC now owns 9,572 shares of the company’s stock valued at $200,000 after buying an additional 2,304 shares in the last quarter. Jump Financial LLC bought a new position in shares of Kura Oncology in the second quarter valued at $223,000. Finally, Axiom Investment Management LLC bought a new position in shares of Kura Oncology in the first quarter valued at $351,000.

About Kura Oncology

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.

Further Reading: Momentum Investing

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.